ArticleJournal of bone metabolism2024
Sarcopenia as the Mobility Phenotype of Aging: Clinical Implications.
Article in Journal of bone metabolism, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Mapping the global landscape of behavioral interventions for sarcopenia in older adults: implications for clinical practice and research prioritization.BMC geriatrics · 2026Pooled it
- Enhancement of Lower Limb Muscle Strength and Reduction of Inflammation in the Elderly: A Randomized, Double-Blind Clinical Trial ComparingNutrients · 2025Trial
- Surface Electromyographic Characteristics of Lower Limb Muscles in Frail Older Adults With Cardiovascular Disease: A Case-Control Study.Journal of cachexia, sarcopenia and muscle · 2026Article
- Article
- Targeting TWEAK to enhance mitochondrial biogenesis and attenuate age-related muscle mass loss.Scientific reports · 2026Article
- Association Between Body Composition, Muscle-to-Weight Ratio, and Functional Disability in Patients with Chronic Non-Specific Low Back Pain: A Cross-Sectional Study.Medicina (Kaunas, Lithuania) · 2026Observational
- Higher Circulating Kynurenine Levels Linked to Higher Risk of Sarcopenia in Older Adults: A Cohort Study and UK Biobank Analysis.Endocrinology and metabolism (Seoul, Korea) · 2026Article
- Elevated Circulating Ceramides 18:0 and 24:1 as a Risk Factor for Sarcopenia: In Vitro, Animal, and Clinical Evidence.Journal of cachexia, sarcopenia and muscle · 2026Article
- Sarcopenia as a Multisystem Disorder-Connections with Neural and Cardiovascular Systems-A Related PRISMA Systematic Literature Review.Life (Basel, Switzerland) · 2026Review
- Establishing Blood-Based Biomarkers for Sarcopenia: Current Challenges and Future Directions.Endocrinology and metabolism (Seoul, Korea) · 2025Article
- Circulating biomarkers associated with walking performance in elderly subjects: exploring miRNAs, metabolic and inflammatory biomarkers.GeroScience · 2025Article
- Validation of the revised multi-sensor-based electronic Short Physical Performance Battery (eSPPB) kiosk in community-dwelling older adults.European geriatric medicine · 2025Article
- Detrimental Effects of β2-Microglobulin on Muscle Metabolism: Evidence From In Vitro, Animal and Human Research.Journal of cachexia, sarcopenia and muscle · 2025Article
- Circulating apelin levels fail to link sarcopenia-related muscle parameters in older adults.The journal of nutrition, health & aging · 2025Article
- Circulating BMP-7 Level is Independent of Sarcopenia in Older Asian Adults.Annals of geriatric medicine and research · 2025Article
- Elevated Circulating Sclerostin Levels in Frail Older Adults: Implications beyond Bone Health.Endocrinology and metabolism (Seoul, Korea) · 2025Article
- Therapeutics for Sarcopenia and Functional Disabilities in Older Adults: A Review of Phase 4 Clinical Trials.Drug design, development and therapy · 2025Review
- Incretin-Based Therapies: A Promising Approach for Modulating Oxidative Stress and Insulin Resistance in Sarcopenia.Journal of bone metabolism · 2024Article
- Beyond Bone: Embracing Osteosarcopenia for Comprehensive Fracture Prevention.Endocrinology and metabolism (Seoul, Korea) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcopenia, which is characterized by an age-related decline in muscle mass and function, poses significant challenges to geriatric care. Its definition has evolved from muscle-specific criteria to include muscle mass, muscle function, and physical performance, recognizing sarcopenia as a physical frailty. Sarcopenia is associated with adverse outcomes, including mortality, falls, fractures, cognitive decline, and admission to long-term care facilities. Neuromechanical factors, protein-energy balance, and muscle protein synthesis-breakdown mechanisms contribute to its pathophysiology. The identification of sarcopenia involves screening tests and a comprehensive assessment of muscle mass, strength, and physical function. Clinical approaches aligned with the principles of comprehensive geriatric assessment prioritize patient-centered care. This assessment aids in identifying issues related to activities of daily living, cognition, mood, nutrition, and social support, alongside other aspects. The general approach to factors underlying muscle loss and functional decline in patients with sarcopenia includes managing chronic diseases and evaluating administered medications, with interventions including exercise and nutrition, as well as evolving pharmacological options. Ongoing research targeting pathways, such as myostatin-activin and exercise mimetics, holds promise for pharmacological interventions. In summary, sarcopenia requires a multifaceted approach, acknowledging its complex etiology and tailoring interventions to individual patient needs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.